SV EN

2010

Grund- och klinisk forskning

(diagnostik, behandling, kliniska prövningar, epidemiologi, neuropsykologi, experimentell forskning, genetik, djurmodeller)

Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E. CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson’s Disease: the Norwegian ParkWest study. J Neurol Neurosurg Psychiatry 2010;81:1080-1086.

Andel R, Crowe M, Feychting M, Pedersen NL, Fratiglioni L, Johansson B, Gatz M. Work Related Exposure to Extremely Low-Frequency Magnetic Fields and Dementia: Results from the Population-Based Study of Dementia in Swedish Twins. J Gerontol A Biol Sci Med Sci 2010. [Epub ahead of print]. Impact factor: 4.2

Andreasen N, Blennow K, Zetterberg H. Neuroinflammation screening in immunotherapy trials against Alzheimer’s disease. Int J Alz Dis 2010:638379.

Anvret A, Ran C, Westerlund M, Thelander AC, Sydow O, Lind C, Håkansson A, Nissbrandt H, Galter D, Carmine Belin A. Possible involvement of a mitochondrial translation initiation factor 3 (Mtif3) variant causing decreased mRNA levels in Parkinson’s disease. Parkinson’s disease 2010, article ID 491751.

Anvret A, Westerlund M, Sydow O, Willows T, Lind C, Galter D and Belin AC. Variations of the CAG trinucleotide repeat in DNA polymerase gamma (POLG1) is associated with Parkinson’s disease in Sweden. Neuroscience Letters 485 (2010) 117–120. Impact Factor: 2.055

Bellander M, Bremer Y, Westerberg Y, Karlsson S, Fürth D, Bergman O, Eriksson E & Bäckman L. Preliminary evidence that allelic variation in the LMX1A gene influences training-related working memory improvement. Neuropsychologia 2010;49:1938-42. IF 4.0

Bjerke M, Portelius E, Minthon L, Wallin A, Anckarsäter H, Anckarsäter R, Andreasen N, Zetterberg H, Andreasson U, Blennow K. Confounding factors influencing amyloid beta concentration in cerebrospinal fluid. Int J Alz Dis 2010;pii 986310.

Björkhem I, Hansson M. Cerebrotendinous Xanthomatosis: An inborn error in bile acid synthesis with defined mutations but still a challenge. Biochem. Biophys. Res. Commun. 396 (2010) 46-49  IF 2.5

Björkhem I, Leoni V, Meaney S. Genetic connections between neurological disorders and cholesterol metabolism. J.Lipid Res.  51 (2010) 2489-2503  IF 6.1

Brunnström H, Rawshani N, Zetterberg H, Blennow K, Minthon L, Passant U, Englund E. Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses. Alzheimers Dement 2010;6:104-109.

Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O. Soluble TNF receptors are associated with Ab metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging 2010;31:1877-1884.

Bäckman L, Lindenberger U, Li SC & Nyberg L. Linking cognitive aging to alterations in dopaminergic neurotransmitter functioning: Recent data and future avenues. Neurosci and Biobehav Rev 2010;34:670-77. IF 9.2

Chalbot S, Zetterberg H, Blennow K, Fladby T, Grundke-Iqbal I, Iqbal K. Cerebrospinal fluid secretory Ca2+-dependent phospholipase A2 activity: a biomarker of blood-cerebrospinal fluid barrier permeability. Neurosci Lett 2010;478:179-183.

Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, Blennow K. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer’s disease. J Alzheimers Dis 2010;22:1281-1288.

Daborg J, von Otter M, Sjölander A, Nilsson S, Minthon L, Gustafson DR, Skoog I, Blennow K, Zetterberg H. Association of the RAGE G82S polymorphism with Alzheimer’s disease. J Neural Transm 2010:117:861-867. Impact factor: 2.6

Darreh-Shori T, Forsberg A, Modiri N, Andreasen N, Blennow K, Kamil C, Ahmded H, Almkvist O, Långström B, Nordberg A. Differential levels of apolipoprotein E and buturylcholinesterase show strong association with pathological signs of Alzheimer´s disease in the brain in vivo. Neurobiol Aging. 2010 Jun 8. (IP 6.634)

De Frias C, Marklund P, Eriksson E, Larsson A, Öman L, Annerbrink K, Bäckman L, Nilsson LG & Nyberg L. Influence of COMT gene polymorphism on fMRI-assessed sustained and transient activity during a working memory task. J Cogn Neurosci 2010;22:1614-22. IF 5.4

Degerman Gunnarsson M, Lindau M, Wall A, Blennow K, Darreh-Shori T, Basu S, Nordberg A, Larsson A, Lannfelt L, Basun H, Kilander L. Pittsburgh Compound-B and Alzheimer’s disease biomarkers in CSF, plasma and urine – an exploratory study. Dement Geriatr Cogn Disord 2010;29:204-212.

De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, Coart E, Hansson O, Minthon L, Zetterberg H, Blennow K, Shaw LM, Trojanowski JQ, for the Alzheimer’s Disease Neuroimaging Initiative. Diagnosis-Independent Alzheimer’s Disease Biomarker Signature in Cognitively Normal Elderly People. Arch Neurol 2010;67:949-956.

Eckerström C, Andreasson U, Olsson E, Rolstad S, Blennow K, Zetterberg H, Malmgren H, Edman A, Wallin A. Combination of hippocampal volume and cerebrospinal fluid biomarkers improves predictive value in mild cognitive impairment. Dement Geriatr Cogn Disord. 2010;29(4):294-300. Epub 2010 Apr 9

Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI. PBT2 rapidly improves cognition in Alzheimer’s disease: additional phase 2 analysis. J Alzheimers Dis 2010;20:509-516.

Fisher H, Nyberg L, Karlsson S, Karlsson P, Brehmer Y, Rieckmann A, MacDonald SWM, Farde L & Bäckman L. Simulating neurocognitive aging: Effects of a dopaminergic antagonist on brain activity during working memory. Biological Psych 2010;67:575-80. IF 8.7

Fjell AM, Walhovd KB, Fennema-Notestine C, McEvoy LK, Hagler DJ, Holland D, Blennow K, Brewer JB, Dale AM, and The Alzheimer’s Disease Neuroimage Initiative. Brain atrophy in healthy aging is related to CSF levels of Abeta1-42. Cereb Cortex 2010;20:2069-2079.

Gao CM, Yam AY, Wang X, Magdangal E, Salisbury C, Peretz D, Zuckermann RN, Connolly MD, Hansson O, Minthon L, Zetterberg H, Blennow K, Fedynyshyn JP, Allauzen S. Ab40 Oligomers Identified as a Potential Biomarker for the Diagnosis of Alzheimer’s Disease. PLoS ONE 2010;5:e15725.

Gil-Bea FJ, Aisa B, Salomon A, Solas M, Del Carmen Mugueta M, Winblad B, Kivipelto M,  Cedazo-Mínguez A, Ramírez MJ . HPA axis dysregulation associated to apolipoprotein E4 genotype in Alzheimer’s disease. J Alzheimers Dis. 2010 Jan 1;22(3):829-38.

Gil-Bea FJ, Solas M, Solomon A, Mugueta C, Winblad B, Kivipelto M, Ramirez MJ, Cedazo-Mínguez A. Insulin levels are decreased in the CSF of women with prodromal Alzheimer´s disease. J Alzheimers Dis. 2010;22(2):405-13.

Gudmundsson P, Skoog I, Waern M, Blennow K, Zetterberg H, Rosengren L, Gustafson D. Is there a CSF biomarker profile related to depression in elderly women? Psychiatry Res 2010;176:174-178.

Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Andreasson U, Londos E, Wallin A, Minthon L, Blennow K. Evaluation of plasma Ab40 and Ab42 as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging 2010;31:357-367.

Hassing L, Dahl AK, Pedersen NL et al. Overweight in midlife is related to lower cognitive function 30 years later: A prospective study with longitudinal assessments. Dementia and Geriatric Cognitive Disorders 2010;29:543-52. Impact factor 2.6

Hedskog L, Petersen CA, Svensson AI, Welander H, Tjernberg LO, Karlström H, Ankarcrona M. Gamma-secretase Complexes Containing Caspase-cleaved Presenilin-1 Increase Intracellular Aβ42/Aβ40 Ratio. J Cell Mol Med. 2010 Nov 3. Impact factor: 4,60

Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O. Evaluation of CSF biomarkers as predictors Alzheimer’s disease: a clinical follow-up study of 4.7 years. J Alzheimers Dis 2010;21:1119-1128.

Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman Å, Blennow K, Rosengren L, Pantoni L, Inzitari D, Wallin A. Cerebrospinal fluid biomarkers of white matter lesions – cross-sectional results from the LADIS study. Eur J Neurol 2010;17:377-382.

Kadir A, Almkvist O, Forsberg A, Wall A, Engler H, Långström B, Nordberg A. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer´s disease. Neurobiol Aging. 2010 Aug 3. (IP 6.634)

Kalpouzos G, Eriksson J, Sjölie D, Molin J & Nyberg L. Neurocognitive systems related to real-world prospective memory. PLOS ONE e13304. IF 4.4

Keller L, Murphy C, Wang HX, Fratiglioni L, Larsson L, Olin M, Gafvels M, Björkhem I, Graff C, Meaney S. A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations. Brain Res. 2010;1344:185-91. Impact factor:  2.62

Kloskowska E, Pham TM, Nilsson T, Zhu S, Oberg J, Codita A, Pedersen LA, Pedersen JT, Malkiewicz K, Winblad B, Folkesson R, Benedikz E. Cognitive impairment in the Tg6590 transgenic rat model of Alzheimer’s disease. J Cell Mol Med. 2010 Jun;14(6B):1816-23. Impact: 4.608

Landgren S, Palmér MS, Skoog I, Minthon L, Wallin A, Andreasen N, Zetterberg M, Blennow K, Zetterberg H. No Association of VEGF Polymorphims with Alzheimer’s Disease. Neuromolecular Med. 2010;12(3):224-8. Impact factor: 4.7

Li SC, Lindenberger U & Bäckman L. Dopaminergic modulation of cognition across the life span. Neurosci and Biobehav Rev 2010;34:625-30. IF 9.2

Luty AA, Kwok JB, Dobson-Stone C, Loy CT, Coupland KG, Karlström H, Sobow T, Tchorzewska J, Maruszak A, Barcikowska M, Panegyres PK, Zekanowski C, Brooks WS, Williams KL, Blair IP, Mather KA, Sachdev PS, Halliday GM, Schofield PR. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol. 2010 Nov;68(5):639-49. Impact factor: 10,75

Lövden M, Bäckman L, Lindenberger U, Schaefer S & Schmiedek F. A theoretical framework for the study of adult cognitive plasticity. Psychol Bulletin 2010;136:659-76. IF 12.0

Marcellino D, Lindqvist E, Schneider M, Müller CE, Fuxe K, Olson L, Galter D. Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice. Neurobiol Dis. 2010 Nov;40(2):460-6  (IF=5.121)

Nordberg A, Rinne J, Kadir A, Långström, The use of PET in Alzheimer´s disease. Nature Rev Neurol 2010; 6: 78-87. (IP 6.511)

Mattsson N, Bremell D, Anckarsäter R, Blennow K, Anckarsäter H, Zetterberg H, Hagberg L. Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurology 2010;10:51.

Mattsson N, Sävman K, Österlundh G, Blennow K, Zetterberg H. Converging molecular pathways in human neural development and degeneration. Neurosci Res 2010;66:330-332.

Mattsson N, Johansson P, Hansson O, Wallin A, Johansson JO, Andreasson U, Andersen O, Haghighi S, Olsson M, Stridsberg M, Svensson J, Blennow K, Zetterberg H. Converging pathways of chromogranin and amyloid metabolism in the brain. J Alzheimers Dis 2010;20:1039-1049.

Mosconi L, Glodzik L, Mistur R, McHugh P, Rich KE, Javier E, Williams S, Pirraglia E, De Santi S, Mehta PD, Zinkowski R, Blennow K, Pratico D, de Leon MJ. Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer’s. Biol Psychiatry 2010;68:913-921.

Olesen PJ, Gustafson DR, Simoni M, Pantoni L, Ostling S, Guo X, Skoog I. Temporal lobe atrophy and white matter lesions are related to major depression over 5 years in the elderly. Neuropsychopharmacology 2010;35(13)2638-45. Impact factor 6.7

Portelius E, Brinkmalm G, Tran A, Andreasson U, Zetterberg H, Westman-Brinkmalm A, Blennow K, Ohrfelt A. Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid. Exp Neurol 2010;223:351-358.

Portelius E, Andreasson U, Ringman JM, Buerger K, Daborg J, Buchhave P, Hansson O, Harmsen A, Gustavsson MK, Hanse E, Galasko D, Hampel H, Blennow K, Zetterberg H. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer’s disease. Mol Neurodegener 2010;5:2.

Portelius E, Dean RA, Gustavsson MK, Andreasson U, Zetterberg H, Siemers E, Blennow K. A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer’s disease. Alzheimers Res Ther 2010;2:7.

Portelius E, Bogdanovic N, Gustavsson MK, Volkmann I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K. Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer’s disease. Acta Neuropathol 2010;120:185-193.

Portelius E, Van Broeck B, Andreasson U, Gustavsson MK, Mercken M, Zetterberg H, Borghys H, Blennow K. Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 2010;21:1005-1012.

Qiu CX, Xu WL, Fratiglioni L. Vascular and psychosocial factors in Alzheimer’s disease: Epidemiologic evidence towards intervention. J Alzheimer Dis 2010 (in press). Impact factor: 4.3

Rieckmann A, Fisher H & Bäckman L. Activation in striatum and medialtemporal lobe during sequence learning in younger and older adults: Relations to performance. Neuroimage 2010;50:1303-12. IF 5.9

Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, de Liano SR, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-372.

Rolstad S, Nordlund A, Eckerström C, Gustavsson MH, Blennow K, Olesen PJ, Zetterberg H, Wallin A. High education may offer protection against tauopathy in patients with mild cognitive impairment. J Alzheimer Dis 2010;21:221-228.

Rolstad S, Berg AI, Bjerke M et al. Amyloid-beta42 is associated with cognitive impairment in healthy elderly and subjective cognitive impairment. JAD 2010;26:135-42. IF 3.0

Ross JM, Öberg J, Brené S, Coppotelli G, Terzioglu M, Pernold K, Goiny M, Sitnikov R, Kehr J, Trifu­no­vic A, Larsson NG, Hoffer BJ and Olson L. High brain lactate is a hallmark aging and caused by a shift in the lactate dehydrogenase A/B ratio. Proc Natl Acad Sci Nov 16; 107: 20087-92, 2010. Impact factor: 9.77

Sehlin D, Söllvander S, Paulie S, Brundin R, Ingelsson M, Lannfelt L, E Pettersson F,  Englund H. Interference from heterophilic antibodies in amyloid-β oligomer ELISAs, Journal of Alzheimers disease 21 (2010) 1295-1301. Impact factor: 4.261.

Selnes P, Blennow K, Zetterberg H, Grambaite R , Rosengren L, Johnsen L, Stenset V, Fladby T. Effects of cerebrovascular disease on amyloid precursor protein metabolites in cerebrospinal fluid. Cerebrospinal Fluid Research 2010;7:10.

Shafaaati M. 24S-Hydroxycholesterol. Studies on regulatory mechanisms behind its formation in the brain and its potential use as a marker for neurodegeneration. Academic Thesis, Karolinska Institutet, 2010

Sjölander A, Zetterberg H, Anderasson U, Minthon L, Blennow K. BACE1 gene variants do not influence BACE1 activity, levels of APP or Abeta isoforms in CSF in Alzheimer’s disease. Mol Neurodegen 2010;5:37.

Stomrud E, Hansson O, Minthon L, Blennow K, Rosén I, Londos E. Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. Neurobiol Aging 2010;31:215-223.

Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E. Correlation of longitudinal CSF biomarkers with cognitive decline in healthy older adults. Arch Neurol 2010;67:217-223.

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon M, Blennow K, Kilander L, Basun H, Lannfelt L. Higher Cathepsin B Levels in Plasma in Alzheimer´s Disease Compared to Healthy Controls. J Alzheimers Dis 2010;22:1223-1230.

Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L. Cystatin C levels are positively correlated with both Abeta42 and Tau Levels in cerebrospinal fluid in persons with Alzheimer’s Disease, mild cognitive impairment, and healthy controls. J Alzheimers Dis 2010;21:471-478.

Sämgård K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E. Cerebrospinal fluid total tau as a marker of Alzheimer’s disease intensity. Int J Geriatr Psychiatry 2010;25:403-410.

Tarling EJ,  Bojanic DD, Tangirala RK, Wang X, Lövgren-Sandblom A, Lusis AJ, Björkhem I, Edwards PA. Impaired development of atherosclerosis in Abcg1-/-Apoe-/- mice; identification of specific oxysterols that accumulate in Abcg1-/-Apoe-/- tissues and are able to induce apoptosis. Arterioscl. Thromb. Vasc. Biol.   30 (2010) 1174-1180  IF 7.2

Thorsell A, Bjerke M, Gobom J, Brunhage E, Vanmechelen E, Andreasen N, Hansson O, Minthon L, Zetterberg H, Blennow K. Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer’s disease. Brain Res 2010;1362:13-22.

Thorvaldsson V, Nordlund A, Reinvang I, Blennow K, Wallin A, Johansson B. Memory in Individuals with Mild Cognitive Impairment in Relation to APOE and CSF Aβ42. Int Psychogeriatr 2010;22:598-606.

Thorvaldsson V, Nordlund A, Reinvang I et al. Memory in individuals with mild cognitive impairment in relation to APOE and CSF Abeta42. Int Psychoger 2010;22:598-606

Wallin AK, Blennow K, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer’s disease. Neurology 2010;74:1531-1537.

Wesnes K, Edgar C, Annas P, Basun H, Andreasen N, Lannfelt L, Zetterberg H, Blennow K, Minthon L. Computerised cognition assessment during acetylcholinesterase treatment in Alzheimer’s Disease. Acta Neurol Scand 2010;122:270-277.

Wicklund L, Richardson NL, Strömberg A-M, Mousavi M, Hovatta O, Nordberg A, Marutle A. ß-amyloid 1-42 oligomers impair function of human embryonic stem cell  derived forbrain cholinergic neurons. Plos One 2010;5: e15600 (IP 4.411)

Wiig EH, Annas P, Basun H, Andreasen N, Lannfelt L, Zetterberg H, Blennow K, Minthon L. The stability of AQT processing speed, ADAS-Cog and MMSE during acetylcholinesterase inhibitor treatment in Alzheimer’s disease. Acta Neurol Scand 2010;121:186-193.

von Otter M, Landgren S, Nilsson S, Lundvall C, Minthon L, Bogdanovic N, Andreasen N, Gustafson DR, Skoog I, Wallin A, Håkansson A, Nissbrandt H, Zetterberg M, Tasa G, Blennow K, Zetterberg H. Kinesin light chain 1 gene haplotypes in three conformational diseases. Neuromolecular Med. 2010;12(3):229-36. Impact factor: 4.7

von Otter M, Landgren S, Nilsson S, Zetterberg M, Celojevic D, Bergström P, Minthon L, Bogdanovic N, Andreasen N, Gustafson DR, Skoog I, Wallin A, Tasa G, Blennow K, Nilsson M, Hammarsten O, Zetterberg H. Nrf2-encoding NFE2L2 haplotypes influence disease progression but not risk in Alzheimer’s disease and age-related cataract. Mech Ageing Dev. 2010;131(2):105-10. Impact factor: 4.7

Xu WL, Caracciolo B, Wang HX, Winblad B, Qiu CX, Fratiglioni L. Accelerated progression from cognitive impairment to dementia in people with diabetes. Diabetes 2010;59:2928-35. Impact factor:  9.02

Zetterberg H, Tullhög K, Hansson O, Minthon L, Londos E, Blennow K. Low incidence of post-lumbar puncture headache in 1089 consecutive memory clinic patients. Eur Neurol 2010;63:326-330.

Zhang Y, Qiu C, Lindberg O, Bronge L, Aspelin P, Bäckman L, Fratiglioni L & Wahlund LO. Acceleration of Hippocampal atrophy in a non-demented elderly population: The SNAC-K study. Int Psychoger 2010;22:14-25. IF 2.5

 

Vård och omsorgsforskning

(vård, rehabilitering, teknologi, primärvård, hälsoekonomi)

Bergvall N, Brinck P, Eek D, Gustavsson A, Wimo A, Winblad B, Jönsson L. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer’s disease. Int Psychogeriatr. 2010 Jul 12:1-13.

Érsek K, Kovács T, Wimo A, Kárpati K, Brodszky V, Péntek M, Jönsson L, Gustavsson A, McDaid D, Kenigsberg PA, Valtonen H, Gulácsi L. Costs of dementia in Hungary. J Nutr Health Aging. 2010 Aug;14(8):633-9.

Gustavsson A, Jönsson L, McShane R, Boada M, Wimo A, Zbrozek AS. Willingness-to-pay for reductions in care need: estimating the value of informal care in Alzheimer’s disease. Int J Geriatr Psychiatry. 2010 Jun;25(6):622-32.

Gustavsson A, Jonsson L, Fillit H, Johansson G, Wimo A, Winblad B. IPECAD5 – Fifth International Pharmaco-Economic Conference on Alzheimer’s Disease. J Nutr Health Aging. 2010;14(5):358-60.

Gustavsson A, Jonsson L, Rapp T, Reynish E, Ousset PJ, Andrieu S, Cantet C, Winblad B, Vellas B, Wimo A; ICTUS Study Group. Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study.J Nutr Health Aging. 2010 Aug;14(8):648-54.

Lindgren H, Eriksson S. (2010) Sociotechnical Integration of Decision Support in the Dementia Domain. Stud Health Technol Inform 157;79-84, IOS Press.

Lindqvist E, Borell L, (2010). The Match between Experienced Difficulties in Everyday Activities after Stroke and Assistive Technology for Cognitive Support. Technology and Disability . 22. 89-98.

Malinowsky C, Almkvist O, Kottorp A & Nygård L. (2010). Ability to manage everyday technology: A comparison of persons with dementia or mild cognitive impairment and older adults without cognitive impairment. Disability & Rehabilitation: Assistive Technology, 5, 462-469.

Sjölund BM, Nordberg G, Wimo A, von Strauss E. Morbidity and physical functioning in old age: differences according to living area. J Am Geriatr Soc. 2010 Oct;58(10):1855-62.

Svidén G A, Tham K, Borell L. (2010). Involvement in everyday life for people with a life threatening illness. Palliative & Supportive Care, 8 (3): 345-52

Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzh Dement. 2010 Mar;6(2):98-103.

Wimo A, Sjölund B, Sköldunger A, Johansson L, Nordberg G, von Strauss E. Incremental patterns in the amount of informal and formal care among non-demented and demented elderly persons results from a 3-year follow-up population-based study. Int J Geriatr Psychiatry. 2010 Jul 26.

Wimo A, Prince M. World Alzheimer Report 2010. The global economic impact of dementia.  Alzheimer Disease International, London, 2010 (Report).

Wimo A, Jonsson L, Zbrozek A. The Resource Utilization in Dementia (RUD) instrument is valid for assessing informal care time in community-living patients with dementia. J Nutr Health Aging. 2010 Aug;14(8):685-90.

 

© 2010 Swedish Brain Power